Condition
Degenerative Disc Disease: Options and What the Evidence Actually Shows
Disc degeneration on MRI is common — and often incidental. Treatment targets pain and function, not the MRI alone.
Anatomy and clinical context
Discs lose height and hydration with age. Annular tears and endplate changes appear on imaging in people with and without pain.
Care focuses on function: rehab, medications, injections, and surgery only for clear indications.
Illustration of the lumbar spine
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Education, graded activity, PT, and multimodal pain strategies.
- Step 2
Injections
Epidurals, facet procedures, and selected regenerative disc injectates in specialty clinics.
- Step 3
Surgery
Fusion or disc replacement when instability, deformity, or refractory stenosis/pain meet surgical criteria.
Where cell therapy fits
Intradiscal regenerative trials are heterogeneous. Patients should demand clear outcome definitions and know that dose limits apply to autologous same-day products.
- Imaging ≠ destiny — correlate with exam and history.
- Same-day products remain dose-constrained.
- Banking younger cells keeps future expanded protocols possible.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.